.jpg)
TOKYO and KOBE, Japan, Dec. 6, 2022 /PRNewswire/ — Imaginative and prescient Care Group and ThinkCyte right now introduced a analysis partnership aimed toward advancing cell remedy in retinal illness. The partnership combines Imaginative and prescient Care Group’s experience in growing investigative mobile therapies with Ghost Cytometry, ThinkCyte’s synthetic intelligence (AI)-driven label-free cell characterization and sorting expertise. The partnership goals to enhance manufacturing and pre-transplant testing for retinal cell remedy transplantation, resulting in the event of cell-based therapies with superior therapeutic outcomes.
The 2 corporations have beforehand collaborated on expertise analysis to extend the purity of goal retinal cell populations utilizing Ghost Cytometry-powered devices. This partnership will develop a brand new strategy for label-free classification and sorting of cell populations used for transplantation. Ghost Cytometry, which mixes proprietary optical expertise and AI to kind cells with out the necessity to use exterior molecular labels, shall be leveraged to categorise and determine retinal cell populations that have been beforehand troublesome to separate utilizing typical approaches. The partnership will drive the applying of Ghost Cytometry additional into the sector of mobile remedy growth and can contribute to Imaginative and prescient Care Group’s mission to supply pioneering cell-based medicines.
“By utilizing ThinkCyte’s platform for label-free classification and sorting of cells with out the usage of antibodies we will remedy crucial cell remedy growth challenges. It could possibly open the potential to make cell therapies with out the necessity to produce clinical-grade antibodies and avoids the restrictions related to the usage of antibodies for therapeutic cell choice,” stated Dr. Masayo Takahashi, CEO at Imaginative and prescient Care Group. “We imagine that this expertise shall be vital for us to pick the mandatory cells in regenerative medication, and the partnership will advance the sector of cell remedy growth.”
“We’re happy to have the ability to contribute our expertise advancing the modern analysis of Imaginative and prescient Care Group, a world chief within the area of regenerative medication for intractable eye ailments, which is taken into account a world unmet medical want,” stated Waichiro Katsuda, CEO at ThinkCyte. “We’re assured that our proprietary label-free cell evaluation and sorting expertise will contribute to many corporations concerned within the quickly rising area of regenerative medication by advancing high quality management and enabling focused sorting of extremely useful cells.”
About ThinkCyte Inc.
ThinkCyte, based in 2016 with workplaces in Tokyo, Japan and San Carlos, California is a biotechnology firm that develops modern scientific devices based mostly on built-in, multidisciplinary applied sciences to allow life science analysis, diagnostics, and therapeutic growth. The corporate pioneered Ghost Cytometry, a proprietary AI-based, label-free cell sorting expertise and companions with main international biopharmaceutical corporations and main tutorial analysis institutes to additional drive pioneering analysis. For extra info, please go to www.thinkcyte.com.
To be taught extra about analysis partnerships or different partnering alternatives with ThinkCyte, contact contact@thinkcyte.com.
About Imaginative and prescient Care Group
Imaginative and prescient Care Group was established by the staff that succeeded on the earth’s first scientific software of iPS cells to resolve all issues confronted by the visually impaired, not restricted to the event of therapies for retinal ailments, based mostly on the Kobe Eye Middle idea of integrating analysis, scientific observe, and affected person care. VC Gene Remedy Inc. for the sensible software of gene remedy and VC Cell Remedy Inc. for the sensible software of cell remedy, as subsidiaries for various functions, and is selling joint analysis with Kobe Eye Middle Hospital. Aiming for “each attainable answer for each affected person,” we’re working to foster seeds and help commercialization, together with collaboration with different corporations, in areas starting from regenerative medication/gene remedy to employment help for low-vision individuals.
Media Contact:
Sheila Burns
512-589-3872
350121@email4pr.com
View authentic content material:https://www.prnewswire.com/news-releases/vision-care-group-and-thinkcyte-announce-research-alliance-in-advanced-cell-therapy-301696131.html
SOURCE ThinkCyte Inc.
